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Proteases are enzymes that regulate the hydrolysis of peptide bonds via a process called 
proteolysis.1 They are essential for many diverse processes including processing protein activity 
and interactions, digestion, blood clotting, host defense, pathogenic infection, viral replication, 
wound healing, disease progression, and they also generate, transduce, and amplify chemical 
signals.2 The proteases’ functions give them a key role in DNA replication and transcription, 
allowing them to control cell replication and death.2 Specific proteases have become targets in 
many diseases such as cancer, neurological disorders, viral infections, inflammation, and arthritis.3 
Inhibitors of  proteases have become of interest as treatment options because they stop proteolysis, 
thus causing the diseased cell to die. One such target protease is the proteasome for the treatment 
of multiple myeloma. However, current approved proteasome inhibitor drugs are not specific 
enough and cause serious side effects to patients, urging the development of new more selective 
inhibitors.12 In this thesis, we present the synthesis of novel Michael acceptor inhibitors for the 
eukaryotic protease that is abundant in multiple myeloma cells, the 26 proteasome, and the main 
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Chapter 1: Introduction 
1.1: Proteases as Targets for Disease Treatment 
Proteases are essential enzymes that regulate the hydrolysis of peptide bonds via a process called 
proteolysis.1 There are 460 different proteases in humans, placing them as the second largest 
enzyme family following the ubiquitin ligases.1 They are involved in processing protein activity, 
protein interactions, cellular information, digestion, blood clotting, pathogenic infection, and 
generate, transduce, and amplify chemical signals.2 Thus, proteases play a key role in DNA 
replication and transcription, allowing them to control cell replication and death.2 A defect in 
proteases function can lead to development of diseases such as cancer, neurological disorders, viral 
infections, inflammation, and arthritis.3  To treat diseases caused by damaged proteases, inhibitors 
of the protease have been developed and sought after. The challenge is to create a protease inhibitor 
with a structure that is highly selective for the desired protease only. Proteases are characterized 
into seven classes based on their active site residue that catalyze substrate cleavage, and into clans 
based on their structure and fold.1 The seven classes include aspartic, cysteine, glutamic, metallo, 
serine, and threonine peptidases, and asparagine peptide lyase.4 
The target protease in Dr. Ekici’s research project is the 26S proteasome, which is part of the 
threonine peptidase class. It is found distributed throughout extracellular and intercellular space of 
cells and is essential in eukaryotic cells for protein degradation and quality control of newly 
synthesized proteins via the ubiquitin-proteasome pathway.1, 5, 7 Protein degradation is vital for the 
survival of cells because it removes toxic misfolded proteins and provides nutrition by recycling 
amino acids during starvation conditions.6 The proteasome was initially a target for anti-
inflammatory agents, however after further research, it was discovered that proteasome inhibitors 
cause apoptosis of different cancer cells, more specifically multiple myeloma.7 It was also 
 2 
discovered that inhibitors were selective to diseased cell, reducing concerns of high toxicity due 
to interference with protein quality control of healthy cells.7 Multiple myeloma cells synthesize a 
large amount of IgG and IgA protein.7, 8, 9 Misfolded IgG proteins are cleaved by proteasomes via 
the endoplasmic reticulum degradation pathway, therefore multiple myeloma cells require a 
unusually large amounts of proteasomes to be present in the cell.7 This increases the sensitivity of 
multiple myeloma cells and makes them great targets for proteasome inhibitors.7, 10 There are 
currently three FDA approved drugs, bortezomib (2003), carfilzomib (2012), and Ixazomib (2015) 
for the treatment of multiple myeloma (Figure 1).12 Unfortunately, these drugs cause serious side 
effects like peripheral neuropathy (bortezomib and ixazomib), or cardiovascular adverse 
effects (carfilzomib).12 With the intent to reduce these side effects, a new, more specific 
proteasome inhibitor must be developed.  
 
Figure 1. FDA approved proteasome inhibitors 
1.2: The 26S Ubiquitin-Proteasome Pathway  
The 26S ubiquitin-proteasome pathway allows for the proteasome to recognize peptides and 
receive them for proteolysis (Figure 2). The 26S proteasome barrel shaped and is made up of three 
subunits: the 20S proteolytic core and two 19S regulatory particles.7 The ubiquitin enzyme labels 
proteins intended for degradation. The 19S regulatory particles of the proteasome recognize the 
labeled proteins and allows them to enter the proteasome in preparation for proteolysis.7 The 
protein then enters the complex four-ring hollow cylindrical structure of the 20S core, which is 
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made of two outer α rings and two inner β rings.7 The β rings contain the catalytic residues 
responsible for proteolytic activity: β1 caspase-like (C-L), β2 trypsin-like (T-L) and β5 
chymotrypsin-like (CT-L).7 
 
Figure 2. 26S ubiquitin-proteasome pathway and active sites.7 
The active cites cleave peptide bonds by the hydroxyl group of the N-terminal threonine acting as 
a nucleophile (Mechanism 1).7, 13 The β1 C-L inactivation via inhibition of the catalytic threonine 
showed no phenotypic defects and no substrate accumulation inside the cell.7, 14 The β2 T-L 
inhibition somewhat decreased growth and degradation of some substrates.7, 14, 16 The inhibition of 
the β5 CT-L is the most significant, as it substantially reduced growth, increased production of 
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misfolded proteins, and caused a buildup of proteasome substrates in the cell.15, 16 Thus, the target 
is the β5 CT-L active site to shut down the function of the proteasome and lead to apoptosis. 
 
Scheme 1: General mechanism of inhibition of the threonine residue7 
1.3: Nomenclature 
To effectively inhibit the function of the 26S proteasome, a peptide sequence that is highly 
selective for the CT-L active site of the 20S core must be synthesized. The ideal peptide sequence 
has been studied to have a Leu amino acid residue at the P3 position to sit in the S3 position of the 
active site.18 It has also been researched that selectivity is enhanced with a bulky group/structure 
at the P2 position for the S2 of the active site.17, 18 The S1 position has also been studied to prefer 
a Leu, Phe, or Tyr residue.18 
 
Figure 3: Active site map of proteases19 
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1.4: Inhibitor design 
Our inhibitor design is an ideal peptide sequence that has high affinity for the active site residues 
and is attached to an electrophilic chemical warhead. Our warhead design consists of a Michael 
acceptor group that is proposed to react with the proteasome’s active site nucleophilic threonine 
oxygen to form a covalent bond (Scheme 2). This covalent modification is expected to be 
irreversible resulting in also so-called suicide inhibition.19 It takes advantage of the enzymes 
catalytic machinery to shut down the enzymes function completely.19 The peptide design has an 
achiral P1 aza-leucine residue aimed to limit the off-target protease activity, it is also 
corresponding to preferred proteasome substrate preference to ensure selectivity.18  
 
Scheme 2: Proposed mechanism of inhibition of the 20S Proteasome by a Michael acceptor 
inhibitor 
1.5: Synthesis strategy  
The synthesis of the Michael Acceptor Inhibitors begins with the peptide backbone. A variety of 
different peptide backbones were synthesized to find the most effective inhibitor. The sequence of 
each tri- and tetrapeptide begins with a protecting group (Pg) followed by amino acid residues that 
dock into the active site positions. The first step in the synthesis of the peptide back bone involves 
the coupling of Pg-AA1-OH to H-AA2-OMe using a general coupling method that utilized NMM 



















































amination using isobutryaldehyde and NaCNBH3. A general synthesis scheme of the tripeptide 
Cbz-Leu-Leu-ALeu sequence precursor is shown in Scheme 3.  
 
Scheme 3: Synthesis of Cbz-Leu-Leu-ALeu precursor 
To synthesize the tetrapeptides, a deprotection and additional coupling step is needed to add 
another amino acid to the peptide sequence. The peptide synthesis of the tetrapeptides begins with 
a Boc protecting group that is removed using 1:1 volume of TFA and DCM to allow for the 
coupling of an additional amino acid and protecting group. The synthesis of the tetrapeptide 
precursor Mp-Phe-Leu-Phe-ALeu is shown in Scheme 4.  
 

























































































































































































The precursor sequences synthesized using the general peptide synthesis methods include: Mp-
Phe-Leu-Phe-ALeu, Cbz-Hph-Leu-Phe-ALeu, Cbz-Leu-Leu-ALeu, and Cbz-Leu-Phe-ALeu 
(Figure 4). 
 
Figure 4: Synthesized Peptide backbone sequences.  
Next, a two-step method was used to synthesize the Michael acceptor warheads. The first step 
was a coupling of monoethyl fumarate to the desired amine using NMM and iBCF (Scheme 5). 
 
Scheme 5: Monoethyl fumarate coupling to amine. 
Step 2 involved the hydrolysis of the ethyl ester group to produce the warhead that is ready to 
couple to the peptide backbone (Scheme 6).  
 












































































A variety of Michael acceptor warheads were synthesized to determine the best compound to 
react with the proteasome’s active site threonine residue. All synthesized warheads are shown in 
Figure 6 (Note that the benzylamide fumaric acid was synthesized by Ms. Kayla Kucway). 
 
Figure 5: All synthesized Michael acceptor warheads.  
The final step in the inhibitor synthesis was the coupling of the peptide backbone to the Michael 
acceptor warhead, which involved the use of EDC, HOBt, and DIPEA. A general coupling of a 
warhead with the Cbz-Leu-Leu-ALeu precursor is shown is Scheme 7. Many final aza-peptide 
Michael acceptor inhibitors were also synthesized by Ms. Leilani Lotti Diaz and Dr. Sarah 
Border. 
 
Scheme 7: Coupling of the peptide backbone to the Michael acceptor warhead.  
 
 
Dibenzylamide fumaric acid Hexylamide fumaric acidIsobutlyamide fumaric acid
Propylamide fumaric  acid Diethylamide fumaric acid






























































1.6 : Inhibition of the Human 20S proteasome by Aza-peptide Michael Acceptor Warheads  
The synthesized aza-peptide Michael acceptor warheads inhibition ability was evaluated in vitro 
by Dr. Sarah Border, and Prof. Ozlem Dogan Ekici. The kinetics data collected displayed in 
Table 1.  
Inhibitor IC50 (µM) 
Cbz-Leu-Leu-ALeu-CH=CH-COOEt 3.7 ± 2.6 
Cbz-Leu-Leu-Aleu-CH=CH-CONHEt 5.5 ± 1.2 
Cbz-Leu-Leu-ALeu-CH=CH-COOBn 13.8 ± 7.3 
Cbz-Leu-Leu-ALeu-CH=CH-CONHBn 0.94 ± 0.2 
Cbz-Leu-Leu-ALeu-CH=CH-CONBn2 1.3 ± 1.1 
Cbz-Leu-Leu-ALeu-CH=CH-CONH-iBu 2.0  ± 0.4 
Cbz-Hph-Leu-Phe-ALeu-CH=CH-COOBn 0.92 ± 0.3 
Cbz-HPh-Leu-Phe-ALeu-CH=CH-CONHEt 3.1 ± 1.5 
Cbz-HPh-Leu-Phe-ALeu-CH=CH-CONHBn 11.2 ± 4.2 
Mp-Hph-Leu-Phe-ALeu-CH=CH-COOEt 5.7 ± 2.5 
Mp-HPh-Leu-Phe-ALeu-CH=CH-CONHBn 0.21 ± 0.05* 
Table 1: InVitro Inhibition Data of 20S Proteasome with Aza-peptice Michael Acceptor 
Inhibitors 
The aza-peptide Michael acceptors displayed low µM-range inhibition of the human 20S 
proteasome. From the kinetic data it can be concluded that the tetrapeptidyl inhibitors are more 
potent than the tripeptidyl inhibitors and the best compound is the tetrapeptide Mp-HPh-Leu-Phe-
ALeu-CH=CH-CONHBn with IC50 = 0.21 µM. Comparing this value to the Cbz-HPh-Leu-Phe-
ALeu-CH=CH-CONHBn IC50 of 11.2 µM, it is observed that the morpholine group improves 
potency approximately 50-fold.  
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Chapter 2: SARS-CoV-2 Main Protease Inhibitors 
2.1: SARS-CoV-2 Introduction 
Over the past two decades, the coronavirus has caused three large-scale outbreaks: severe acute 
respiratory syndrome (SARS) in 2003, Middle Eastern respiratory syndrome (MERS) in 2012, and 
now severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019.21 To date, the novel 
coronavirus SARS-CoV-2 has affected 251 million people worldwide and caused over 5 million 
deaths.27 The COVID-19 pandemic caused by SARS-CoV-2 spiked panic across the world and 
urged for the development of treatments or vaccines. Due to SARS-CoV-2’s ability to spread so 
quickly, the world raced to create a vaccine to control infection rate. As of today, there are over 
20 SARS-CoV-2 vaccines developed between the United States and other countries. The vaccines 
developed include viral vector, inactivated, RNA, protein subunit, and DNA vaccines. These 
vaccines, particularly the mRNA vaccines, have been proven highly effective. Data so far indicates 
that booster shots may require annually.  
The main concern for a mutation site is the SARS-CoV-2 spike protein, which mediates the virus 
entry into the host cells.20 With the emergence of new variants of SARS-CoV-2, and the 
unpredictability of the mutation sites, future coronavirus outbreaks are possible. Therefore, it is 
crucial to develop new therapeutics that can target and affect all variants of the virus. To be able 
to treat all novel coronavirus cases post-infection, the main protease of SARS-CoV-2, the Mpro, 
has emerged as the best target for treatment.  SARS-CoV-2 Mpro is essential for survival of the 
virus and does not mutate between variants.22, 23 The Mpro structure is conserved between all 
coronaviruses and mutations to the protease are lethal to the virus.22 Thus, the Mpro is an excellent 
target for new therapeutic inhibitors to treat SARS-CoV-2 and other future coronavirus variants. 
Based off a research report published by A. Shirit, the key interactions of SARS-CoV and SARS-
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CoV-2 main proteases are conserved.24 Utilizing this information and the revealed X-ray crystal 
structure (PDB ID: 6LU7), Dr. Ozlem Dogan Ekici has proposed novel inhibitor structures 
designed specifically for the SARS-CoV-2 Mpro to inhibit the virus’ replication.  
2.2: Preliminary Data  
The SARS-CoV-2 Mpro is a cysteine protease with preference for the tetrapeptide sequence Ala-
Val-Leu-Gln.23 144 inhibitors were designed and proposed to be suicide inhibitors that aim to 
alkylate the active site of the Mpro. More specifically, the inhibitor’s electrophilic warhead is 
expected to react with the nucleophilic cysteinyl sulfur atom of the SARS-CoV-2 Mpro to form a 
covalent bond, thus inhibiting the protease’s function and prohibiting replication. The novel 
inhibitors energetic scores for the docked poses were compared to determine the best inhibitor 
design (Figure 6) by Dr. William Coldren. The docking score of a known broad spectrum Michael 
acceptor 3C protease (old name for Mpro) inhibitor (red dot, Figure 6), N3, and a newly published 
peptidomimetic 𝛼-ketoamide inhibitor (yellow dot, Figure 6), 13B, were used as reference points. 
From the docking scores, it was concluded that 23 of the proposed designs have better docking 
scores (more negative) than the reference inhibitor, N3, and of those 23, 15 performed better than 
13B. Also, to compare inhibitory activity, the Tanimoto similarity scores of the novel designs were 
also compared to the reference compound N3. The top 23 compounds all received a score of 0.75 
and higher, suggesting they will inhibit the SARS-CoV-2 Mpro. A molecular dynamics simulation 
was also conducted for the top performing compound and the results gave a RMSD value less than 
2.5 Å, suggesting excellent binding with the Mpro.  
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Figure 6: Docking scores of 144 novel inhibitor designs compared to N3 (red dot) and 13B 
(yellow). 
2.3 Inhibitor Design 
The inhibitor designs consist of tri- and tetrapeptidyl frameworks with a protecting group and an 
electrophilic warhead. Investigators at Pfizer have discovered the Mpro has a strong preference for 
inhibitors with a Gln at the P1 position, small hydrophobic residues at the P2 and P4 position, and 
a 2-pyridone group embedded in the compounds structure.25, 26 As for the warhead, the best 
performing inhibitors based on preliminary data in our above-mentioned studies were obtained 
with epoxides and ketone warheads. Using this information, a framework of proposed inhibitors 
was designed to be synthesized.  
2.4: Synthesis Strategy 
To optimize time and synthetic effort, a solid-phase based approach is followed to synthesize the 
peptide backbones. A general procedure for the solid-phase synthesis method of the peptide 
backbone is shown in Scheme 8 to synthesize Cbz-Leu-Leu-Leu-OH. The preferred peptide 
sequence for SARS-CoV-2 Mpro is Ala-Val-Leu-Gln, which will be also synthesized via solid-
phase peptide synthesis similar to as outlined in Scheme 8. 
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Scheme 8: Solid phase synthesis of Cbz-Leu-Leu-Leu-OH 
To synthesize one of the proposed warheads, the epoxide warhead, for the SARS-CoV-2 inhibitors, 
two different methods were attempted. The first method involved the synthesis of the R,R or S,S 
epoxide starting from L- or D-diethyl tartrate, respectively (Scheme 9). This approach involved a 
two-step substitution with bromine, followed by an epoxidation step using Na. The second method 
involved reacting diethyl fumarate with tert-butyl lithium and tert-butyl hydroperoxide to produce 
a trans epoxide (Scheme 10). Studies are ongoing in Dr. Ekici’s laboratory to optimize the 
conditions for these two syntheses. Once these warheads are synthesized, the peptide backbone 
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Scheme 9: R,R epoxide synthesis from diethyl-L-(+)-tartrate. 
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Experimental 
Procedures for synthesized compounds 
General NMM and iBCF Coupling Procedure: 
Two oven-dried round bottom flasks were utilized and labeled as flasks A and B. To flask A was 
added Pg-AA1-COOH (10 mmols, 1 eq) in dry THF (100 mL) and brought to -15˚C. To flask B 
was added H-AA2-OMe (10 mmols, 1 eq) in dry THF (100 mL) and brought to -15˚C. NMM (11 
mmols, 1.1 eq) was added to flask A dropwise via syringe and left to react for 10 minutes. Once 
the 10 minutes elapsed, iBCF (10 mmols, 1 eq) was added to flask A and allowed to react for 30 
minutes. 15 minutes into the iBCF reaction, NMM (11 mmols, 1.1 eq.) was added to flask B and 
left to react for 15 minutes. Flask B was then added to flask A and left to stir at -15˚C for 1 hour, 
then allowed to warm to room temperature to react overnight. The reaction was then 
concentrated under reduced pressure. The residue was treated with EtOAc (100 mL) and diH2O 
(100 mL). The organic layer was washed 3x with 1 M HCl (100 mL), saturated NaHCO3 (100 
mL), brine, dried over Na2SO4, filtered, and concentrated under reduced pressure.  
Formation of hydrazide procedure: 
A solution of Pg-AA1-AA2-OMe (16 mmols, 1 eq) in MeOH (50 mL) was treated with excess 
hydrazine (160 mmols, 10 eq) and allowed to react for 16 hours at room temperature. MeOH and 
hydrazine were removed under reduced pressure. 
Reductive Amination Procedure – Step 1:  
A solution of Pg-AA1-AA2-NHNH2 (15 mmols, 1eq) was dissolved in dry THF (100 mL)and 
treated with isobutyraldehyde (22.5 mmols, 1.5 eq) dropwise at room temperature. The reaction 
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mixture was left to stir for 16 hours. Solvent was removed under reduced pressure and crude was 
purified using flash column chromatography (10% MeOH/ DCM).  
Reductive Amination Procedure – Step 2 (NaCNBH3 Reduction): 
Pg-AA1-AA2-NHNCHCH(CH3)2 (15 mmols, 1 eq) was dissolved in MeOH (100 mL) at room 
temperature. NaCNBH3 (60 mmols, 4 eq) was added to the solution followed by dropwise 
addition of Acetic acid via syringe and allowed to react for 24 hours. Solution pH was then 
adjusted to pH 10 using 1M NaOH. Solvents were removed under reduced pressure. Residue was 
dissolved in EtOAc (100 mL) and extracted with diH2O (100 mL)  3x, brine (100 mL) 3x, 
organic layer was collected and dried over Na2SO4. EtOAc was then removed under reduced 
pressure. 
Hydrolysis procedure of Monoethyl fumarate amides: 
Monoethyl fumarate amide (10 mmol, 1 eq) was dissolved in EtOH (100 mL) and brought to 
0˚C. 1 M NaOH (10 mmols, 1eq) was added dropwise via syringe. The solution was allowed to 
stir for 45 minutes at 0˚C, then moved to room temperature for 90 minutes. EtOH was removed 
under reduced pressure. Residue was dissolved in diH2O (100 mL) and acidified to pH 2 using 1 
M HCl. Solution was extracted with ether (100 mL) three time, and aqueous layer was collected. 
DiH2O was then removed under reduced pressure. 
TFA/DCM deprotection procedure of Boc protecting group: 
Boc-AA1-AA2-OMe (30 mmols, 1 eq) sequence was dissolved in DCM (15 mL) and brought to 
0˚C. Solution was then treated with an equal volume of TFA (15 mL). The reaction was allowed 
to stir at 0˚C for 30 minutes, then moved to room temperature for 1 hr. TFA and DCM were then 
removed under reduced pressure. 
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Morpholine coupling procedure:  
 
H-AA1-AA2-AA3 -OMe (1.24 mmol, 1 eq) was dissolved in DMF(10 mL) and brought to 0˚C. 
The solution was treated with morpholinoacetic acid (1.612 mmols, 1.3 eq) followed by 
dropwise addition of DIPEA (2.48mmols, 2 eq). In a separate round bottom flask, PyBop (1.984 
mmols, 1.6 eq) was dissolved in DMF(10 mL) and added to the reaction solution at 0˚C. The 
solution was allowed to stir at 0˚C and left to reach room temperature overnight. DMF was 
removed under reduced pressure and residue dissolved in EtOAc(10 mL) and extracted with 
diH2O (10 mL), saturated NaHCO3 (10 mL), and brine (10 mL), the organic layer was collected 
and dried over Na2SO4. Crude was then triturated using diethyl ether, and subsequently purified 
by silica gel chromatography (10% MeOH/DCM).  
Aza-peptide Michael acceptor inhibitor synthesis coupling procedure: 
A solution of Pg-AA1-AA2-AA3-NHNHCH2CH(CH3)2 (0.314 mmols, 1eq) in dry DMF (20 mL) 
at 0˚C was treated with HOBt (1.25 mmols, 4 eq) and R(2)-amide fumaric acid (1.25 mmols, 4eq) 
and allowed to stir for 15 min. The solution was then treated with EDC (1.25 mmols, 4 eq) and left 
to stir for 5 min at 0°C. Reaction was then stirred for 16 hours at room temperature. DMF was 
removed under reduced pressure and crude was dissolved in EtOAc (10 mL) and extracted 3x with 
saturated NaHCO3 (10 mL) and brine (10 mL) then dried over Na2SO4. Crude was purified by 
silica gel chromatography (5% MeOH/DCM). 
Solid phase peptide synthesis procedure: 
Fmoc-Leu-Wang resin (0.160 mmols, 1 eq) was tested to be yellow using a Kaiser test and added 
to a separatory solid phase synthesis funnel. The beads were then swelled in DCM (10 mL), and 
rinsed 2x with DMF (10 mL). To the funnel, 20% piperdine in DMF (7 mL) was added and the 
mixture rotated for 15 min. The resin was then rinsed with DMF and another volume of 20% 
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piperdine in DMF (7 mL) was added to the funnel to rotate for an additional 5 min. The 
piperidine solution was then washed off and the resin was thoroughly rinsed 3x with DMF (10 
mL), DCM (10 mL), DMF (10 mL), and the Kaiser test appeared blue indicating free amine. 
Next, a solution of HOBt (0.64 mmols, 4 eq), HBTU (0.64 mmols, 4 eq) , and Peptide sequence-
OH (0.64 mmols, 4 eq) in DMF (10 mL)was added to the funnel, DIPEA (0.64 mmols, 4 eq)was 
then added dropwise, and the reaction was rotated for 30 min. The resin was then filtered and 
rinsed with DMF (10 mL). The reaction was repeated once on the same scale and under the same 
conditions. A Kaiser test was performed and appeared colorless indicating coupling is complete. 
To the funnel, 20% piperdine in DMF (7 mL) was added and the mixture rotated for 15 min. The 
piperdine solution was drained, beads were washed with DMF (10 mL) and a second volume 
20% piperdine in DMF (7 mL) was added and the mixture was rotated for 5 min. A blue Kaiser 
test indicated free amine. Following, a solution of HOBt (0.64 mmols, 4 eq) , HBTU (0.64 
mmols, 4 eq) , and Fmoc-peptide sequence-OH (0.64 mmols, 4 eq) in dry DMF was added to the 
funnel, with DIPEA (0.64 mmols, 4 eq) added dropwise. The reaction was rotated for 30 min. 
The reaction was repeated once on the same scale and under the same conditions. The solution 
was then drained, and beads were rinsed 3x with DMF (10 mL), DCM (10 mL), DMF (10 mL). 
A Kaiser test was performed and appeared clear. The solution was thoroughly washed with DCM 
(30 mL) and a solution of 1:1 DCM/TFA (10 mL) was added to the funnel and rotated for 1 hr. 
Following, the solution was drained from the beads. The beads were exhaustively rinsed with 
additional DCM (30 mL) to ensure complete collection of cleaved products. The organic solution 
was concentrated in vacuum.  
Aza-Gln Side Chain Synthesis (step 1): 
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To a 50 mL round bottom, tert-Butyl-3-bromopropionate (3.932 mol, 1 eq) and 
tetrabutylammonium iodide (3.932 mmol, 1 eq) were added and allowed to pre-stir for 45 min at 
55˚C in DMF (10 mL). Following, a solution of 9-Fluorenylmethyl Carbazate (3.932 mmol, 1 
eq) in DMF (10 mL) was added and the solution was allowed to stir at 55˚C for 48 hr. DMF was 
removed using nitrogen gas. Residue was dissolved in EtOAc (10 mL) and extracted with diH2O 
(10 mL), organic layer was collected and dried over Na2SO4. EtOAc was then removed under 
reduced pressure. Crude was then recrystallized using DCM. Collected solid was starting 
material, DCM was then removed under reduced pressure. Crude was titrated using diethyl ether 
and remaining crude was purified using column chromatography in 5% MeOH/DCM. Collected 
spots were again purified using column chromatography in 2:3 EtOAc: hexanes. 
Epoxide Warhead Synthesis Step 1 (bromination):  
Diethyl L-(+)-tartrate (48.5 mmol, 1 eq) was dissolved in of 33% HBr/AcOHneat (35 mL). The 
reaction was backfilled with N2 and allowed to stir overnight at RT. Excess 33% HBr/AcOH was 
removed under reduced pressure. 
Epoxide warhead synthesis Step 2 (acetoxy to hydroxy group): 
Diethyl 2-acetoxy-3-bromosuccinate (42.3 mmol, 1 eq) was treated with 33% HBr/AcOH (32 
mL) in EtOH (200 mL) under reflux for 5 h. Following, and excess HBr/AcOH and solvent were 







RA-1-1 (Methyl ((benzyloxy)carbonyl)-L-leucyl-L-leucinate). Refer to general NMM and 
iBCF Coupling procedure for method and work up. Product produced as a white solid (6.26 g, 16 
mmol, 80% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.88 (m, Leu CH3, 12H), 1.14-1.62 (m, 
Leu CH2+CH, 6H), 3.60 (s, OMe, 3H), 4.05 (m, CH, 1H), 4.28 (t, CH, 1H), 5.02 (s, Cbz CH2, 
2H), 7.35 (m, Phenyl +NH, 6H), 8.24 (d, NH, 1H). HRMS (ESI) calcd for [C21H32N2O5+Na] + 
415.2311, found 415.2746 (M+23), and 807.5566 (2M+23).  
 
II 
RA-1-3 (Benzyl ((S)-1-(((S)-1-hydrazineyl-4-methyl-1-oxopentan-2-yl) amino)-4-methyl-1-
oxopentan-2-yl) carbamate). Refer to formation of hydrazide procedure for method and work 
up. Product produced as a white solid. (10.89 g, quantitative yield) 1H NMR (DMSO-d6, 
400MHz) d: 0.87 (m, Leu CH3, 12H), 1.42 (m, Leu CH2+CH, 6H), 4.07 (m, NH2, 2H), 4.30 (m, 
2CH, 2H), 5.06 (s, Cbz CH2, 2H), 7.37 (m, Phenyl +NH, 6H), 7.86 (d, NH, 1H), 8.53 (d, NH, 




















RA-1-5 (Benzyl ((S)-4-methyl-1-(((S)-4-methyl-1-(2-((Z)-2-methylpropylidene) 
hydrazineyl)-1-oxopentan-2-yl) amino)-1-oxopentan-2-yl) carbamate). Reductive Amination 
Procedure – Step 1 for method and work up. Product produced as a white solid (6.85 g, 15.5 
mmol, 95% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.86-1.03 (m, Leu CH3, 18H), 1.43-1.76(t, 
Leu CH2+CH, 7H), 4.06 (m, C(alpha), 1H), 4.28 (m, C (alpha, 1H), 5.02 (m, Cbz CH2, 2H), 7.37 
(m, Phenyl +2NH, 8H), 7.78-7.97(d, =CH-, 1H), 10.87-11.11(s, NH, 1H). HRMS (ESI) calcd for 
[C24H38N4O4+Na] + 469.2893, found 469.3223 (M+23), and 915.76508 (2M+23). 
 
IV 
RA-1-6 (Benzyl ((S)-1-(((S)-1-(2-isobutylhydrazineyl)-4-methyl-1-oxopentan-2-yl) amino)-4-
methyl-1-oxopentan-2-yl) carbamate). Refer to reductive Amination Procedure – Step 2 
(NaCNBH3 Reduction) for method and work up. Product produced as a white solid (4.8 g, 10.7 
mmol, 70 % yield). 1H NMR (DMSO-d6, 400MHz) d: 0.88-1.05 (m, Leu CH3, 18H), 1.43-
1.62(m, Leu CH2+CH, 7H), 4.05 (m, C (alpha), 1H), 4.83(m, NH,1H), 5.03 (s, Cbz CH2, 2H), 
7.35 (m, Phenyl +NH, 6H), 7.84 (s, NH, 1H), 9.36 (s, NH, 1H). HRMS (ESI) calcd for 























RA-1-7 (Benzyl ((S)-4-methyl-1-(((S)-4-methyl-1-(2-((Z)-2-methylpropylidene) 
hydrazineyl)-1-oxopentan-2-yl) amino)-1-oxopentan-2-yl) carbamate). Refer to Reductive 
Amination Procedure – Step 1 for method and work up. Product produced as a white solid (0.97 
g, 2.17 mmol, 68% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.86-1.05 (m, Leu CH3, 18H), 1.44-
1.76(m, Leu CH2+CH, 7H), 4.06 (m, C (alpha), 1H), 4.28 (m, C (alpha, 1H), 5.03 (s, Cbz CH2, 
2H), 7.35 (m, Phenyl +1NH, 6H), 7.77(d, =CH-, 1H), 7.94 (d, NH,1H), 10.85-11.03(s, NH, 1H). 




RA-1-8 (Benzyl ((S)-1-(((S)-1-(2-isobutylhydrazineyl)-4-methyl-1-oxopentan-2-yl) amino)-4-
methyl-1-oxopentan-2-yl) carbamate). Refer to reductive Amination Procedure – Step 2 
(NaCNBH3 Reduction) for method and work up. Product produced as a white solid (2.212 g, 
quantitative yield). 1H NMR (DMSO-d6, 400MHz) d: 0.87-1.04 (m, Leu CH3, 18H), 1.44-1.64 





















(s, Cbz CH2, 2H), 7.35 (m, Phenyl +NH, 6H), 7.84 (d, NH, 1H), 9.39 (s, NH, 1H). HRMS (ESI) 
calcd for [C24H40N4O4+H] + 449.3059, found 449.3554 (M+1). 
 
VII 
RA-1-12 (methyl ((benzyloxy)carbonyl)-L-phenylalanyl-L-leucinate) Refer to general NMM 
and iBCF Coupling procedure for method and work up. Product produced as a white solid. (4.47 
g, 10.48 mmol, 52% yield) 1H NMR (DMSO-d6, 400MHz) d: 0.86-0.92 (m, Leu CH3, 6H), 1.59-
1.84 (m, Leu CH+ Leu CH2, 3H), 2.74 (t, Phe CH2, 1H), 3.00 (d, Phe CH3, 1H), 3.62 (s, OMe, 
3H), 4.32 (q, C (alpha), 2H), 4.94 (s, CH2 (Cbz), 2H), 7.30 (m, Phenyl groups, 10H), 7.47 (d, 
NH, 1H), 8.38 (d, NH, 1H). HRMS (ESI) calcd for [C24H30N2O5+Na] + 449.2155, found 
449.2852 (M+23), and 875.5816 (2M+23).  
 
VIII 
RA-1-13 (ethyl (E)-4-(diethylamino)-4-oxobut-2-enoate). Refer to general NMM and iBCF 
Coupling procedure for method and work up. Product produced as a pink oil. (2.38 g, 
quantitative yield). 1H NMR (DMSO-d6, 400MHz) d: 1.06-1.12 (m, amine CH3, 6H), 1.24 (m, 
CH3, 3H), 3.24 (m, 2CH2, 4H), 4.18 (q, CH2-O, 2H), 6.58 (d, H, 1H), 7.35 (d, H,1H). HRMS 















RA-1-14 (ethyl (E)-4-(dibenzylamino)-4-oxobut-2-enoate) Refer to general NMM and iBCF 
Coupling procedure for method and work up. Product produced as a yellow oil. (5.3756 g, 16.63 
mmols, 83.2% yield). 1H NMR (DMSO-d6, 400MHz) d: 1.23 (m, CH3 , 3H), 4.16 (q, CH2 , 2H), 
4.69 (d, CH2, 2H), 6.74 (d, H, 1H), 7.20 (d, H, 1H), 7.44 (m, phenyl group, 10H). HRMS (ESI) 
calcd for [C20H21NO3+Na] +  346.1521, found 346.1764 (M+23), 669.3618 (2M+23). 
 
X 
RA-1-15 (((benzyloxy)carbonyl)-L-phenylalanyl-L-leucine). Refer to hydrolysis of monoethyl 
fumarate amides procedure for method and work up. Product produced as a white solid. (3.04 g, 
7.38 mmols, 97.0% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.86-0.91 (m, Leu CH3, 6H), 1.55-
1.65 (m, Leu CH+ Leu CH2, 3H), 2.75 (t, Phe CH2, 1H), 3.01 (d, Phe CH3, 1H), 4.04 (q, 2C 
(alpha), 2H), 4.94 (s, CH2 (Cbz), 2H), 7.31 (m, Phenyl groups, 10H), 7.46 (d, NH, 1H), 8.22 (d, 
NH, 1H), 12.54 (s, OH, 1H). HRMS (ESI) calcd for [C23H28N2O5+Na] + 435.1998, 















RA-1-18 (ethyl (E)-4-(dibenzylamino)-4-oxobut-2-enoate) Refer to general NMM and iBCF 
Coupling procedure for method and work up. Product produced as a Yellow Oil. (3.96 g, 12.25 
mmols, 61% yield). 1H NMR (DMSO-d6, 400MHz) d: 1.21 (m, CH3, 3H), 4.03- 4.17 (m. CH2, 
2H), 4.61- 4.68 (d, dibenzyl CH2, 4H), 6.67-6.70 (d, tran H, 1H), 7.19-7.28 (m, Phenyl, 10H), 
7.42 (d, trans H, 1H). HRMS (ESI) calcd for [C20H21NO3+H] + 324.1521, found 324.1955 (M+1), 
and 647.3832 (2M+1). 
 
XII 
RA-1-20 (ethyl (E)-4-oxo-4-(propylamino)but-2-enoate). Refer to general NMM and iBCF 
Coupling procedure for method and work up. Product produced as a yellow solid. (3.0981g, 
16.72 mmols, 83.6% yield). 1H NMR (DMSO-d6, 400MHz) d: 8.49 (s, NH, 1 H), 7.01 (d, H 
trans, 1 H), 6.55 (d, H trans, 1 H), 4.17 (q, CH2, 2 H), 3.11 (q, CH2, 2 H), 1.59 (m, CH2, 2H), 
1.25 (m, CH3, 3 H), 0.86 (M, CH3, 3 H). HRMS (ESI) calcd for [C9H17NO3+Na] + 208.1052, 













RA-1-21 ((E)-4-(diethylamino)-4-oxobut-2-enoic acid). Refer to hydrolysis of monoethyl 
fumarate amides procedure for method and work up. Product produced as a Clear Oil. (48mg, 
0.282 mmols, 12.0% yield). 1H NMR (DMSO-d6, 400MHz) d: 1.06-1.41 (m, CH3, 6H), 3.35 (m, 
CH2, 4H), 6.54 (d, trans H, 1H), 7.25 (d, trans H, 1H), 12.87 (s, OH, 1H). HRMS (ESI) calcd for 
[C8H13NO3+Na] + 194.0895, found 194.0920 (M+23), and 365.1947 (2M+23). 
 
XIV 
RA-1-22 (ethyl (E)-4-(butylamino)-4-oxobut-2-enoate). Refer to general NMM and iBCF 
Coupling procedure for method and work up. Product produced as a yellow solid. (2.5231 g, 12.6 
mmols, 63.0% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.86 (m, CH3, 3H), 1.16-1.24 (m, 
CH2+CH3, 5H), 1.41 (m, CH2, 2H), 2.95 (m, CH2, 2H), 4.17 (m, CH2, 2H), 6.54 (d, trans H, 1H), 
6.99 (d, trans H, 1H), 8.47 (s, NH, 1H). HRMS (ESI) calcd for [C10H17NO3+Na] + 222.1208, 
found 222.1367 (M+23), and 421.2792 (2M+23). 
 
XV 
RA-1-23 (ethyl (E)-4-(isobutylamino)-4-oxobut-2-enoate). Refer to general NMM and iBCF 
Coupling procedure for method and work up. Product produced as a yellow solid. (2.74 g, 
13.8mmols, 69.0% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.86 (m, 2CH2, 6H), 1.25 (m, CH3, 
3H), 1.72 (m, CH, 1H), 3.00 (m, CH2, 2H), 4,19 (q, CH2, 2H), 6.56 (d, trans H, 1H), 7.04 (d, 











RA-1-24 ((E)-4-(diethylamino)-4-oxobut-2-enoic acid). Refer to hydrolysis of monoethyl 
fumarate amides procedure for method and work up. Product produced as a pink solid. (2.07 g, 
12.20 mmols, 91% yield). 1H NMR (DMSO-d6, 400MHz) d: 1.04-1.11 (m, 2 CH3 , 6 H), 3.33 
(m, 2CH2 + H2O, 6H), 6.51 ( d, H trans, 1 H), 6.75 (d, H trans, 1 H). HRMS (ESI) calcd for 
[C8H13NO3+Na] + 194.0895, found 194.1122 (M+23). 
 
XVII 
RA-1-25 (ethyl (E)-4-(diethylamino)-4-oxobut-2-enoate). Refer to general NMM and iBCF 
coupling procedure for method and work up. Product produced as a red oil. (2.6486 g, 13.40 
mmols, 67%). 1H NMR (DMSO-d6, 400MHz) d: 0.90- 1.06 (m, 2CH3, 6 H), 1.12- 1.24 (m, CH3, 
3 H), 3.19- 3.30 (m, 2 N-CH2, 4 H), 4.19 (m, O-CH2, 2H), 6.57 (d, H trans, 1 H), 7.35 (d, H trans, 




RA-1-28 (ethyl (E)-4-(ethylamino)-4-oxobut-2-enoate). Refer to general NMM and iBCF 











mmols, 37% yield).  1H NMR (DMSO-d6, 400MHz) d: 0.88- 1.06 (m, CH3, 3 H), 1.24 (m, CH3, 
3 H), 3.18 (m, N-CH2, 2 H), 4.18 (m, O-CH2, 2 H), 6.57 (d, H trans, 1 H), 6.96 (d, H trans, 1 H), 
8.52 (s, NH, 1 H). HRMS (ESI) calcd for [C8H13NO3+Na] + 194.0895, found 194.1014 (M+23), 
and 365.2085 (2M+23). 
 
XIX 
RA-1-29 (methyl (tert-butoxycarbonyl)leucylphenylalaninate). Refer to general NMM and 
iBCF coupling procedure for method and work up. Product produced as a white solid. (12.24 g, 
31.2 mmols, 78% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.84 (m, 2 CH3, 6 H). 1.18- 1.52 (m, 
2 CH3 + CH2 + alpha C, 12H), 2.95 – 3.01 (m, CH2, 2 H), 3.58 (s, CH3, 3 H), 3.96 ( q, alpha C, 
1H), 4.49 (q, alpha C, 1 H), 6.80 (d, NH, 1 H), 7.22- 7.25 (m, phenyl, 5 H), 8.13 (d, NH, 1H). 




RA-1-30 (methyl leucylphenylalaninate). Refer to TFA/DCM deprotection of Boc protecting 
group procedure for method and work up. Product produced as a Clear oil. (9.12 g, 31.2 mmols, 















1.65 (q, apla C, 1 H), 3.00-3.06 (m, CH2, 2 H), 3.60 (s, CH3, 3 H), 3.77 (m, alpha C, 1 H), 4.56 
(q, alpha C, 1 H), 7.27 (m, phenyl, 5 H), 8.12 (s, NH, 1 H), 8.98 (d, NH, 1 H).  HRMS (ESI) 
calcd for [C16H24N2O3+Na] + 293.1787, found 293.2200 (M+1), and 585.4321 (2M+1). 
 
XXI 
RA-1-31 ((E)-4-oxo-4-(propylamino)but-2-enoic acid). Refer to hydrolysis of monoethyl 
fumarate amides procedure for method and work up. Product produced as a yellow solid. (0.430 
g, 2.74 mmols, 99% yield). 1H NMR (MeOD-d4, 400MHz) d: 0.9408 (m, CH3, 3 H), 1.5496- 
1.5684 (q, CH2, 2 H), 3.2114 (t, CH2, 2 H), 6.6364 (d, H trans, 1 H), 6.7666 (d, H trans, 1 H). 




RA-1-32 (ethyl (E)-4-(hexylamino)-4-oxobut-2-enoate). Refer to general NMM and iBCF 
Coupling procedure for method and work up. Product produced as a white solid. (3.50 g, 15.4 
mmols, 77% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.8611 (m, CH3, 3 H). 1.2327 (m, 4 CH3, 
9 H), 1.4273 (m, CH2, 2 H), 3.1436 (q, CH2, 2 H), 4.1758 (q, CH2, 2 H), 6.5645 (d, H trans, 1 H), 
6.9833 (d, H trans, 1 H), 8.4814 (s, NH, 1 H). HRMS (ESI) calcd for [C10H17NO3+Na] + 










RA-1-33 ((E)-4-(dibenzylamino)-4-oxobut-2-enoic acid). Refer to hydrolysis of monoethyl 
fumarate amides procedure for method and work up. Product produced as a yellow solid. (0.56 g, 
1.597 mmols, 98% yield). 1H NMR (DMSO-d6, 400MHz) d: 4.5626 (m, 2 CH2, 4 H), 6.6908 (d, 
H trans, 1 H), 6.8150 (d, H trans, 1 H), 7.2539- 7.3532 (m, phenyl, 10 H). HRMS (ESI) calcd for 
[C18H17NO3+Na] + 318.1208, 318.1456 (M+23), and 613.2994 (2M+23). 
 
XXIV 
RA-1-34 ((E)-4-(isobutylamino)-4-oxobut-2-enoic acid). Refer to hydrolysis of monoethyl 
fumarate amides procedure for method and work up. Product produced as a yellow solid. (2.90 g, 
11.22 mmols, 86% yield). 1H NMR: Solvent: MeOD-d4. 0.9194- 0.9361 (m, 2 CH3, 6 H), 1.8152 
(m, alpha C, 1 H), 3.0689- 3.0862 (d, CH2, 2 H), 6.6213-6.6601 (d, trans H, 1 H), 6.7692- 6.8080 
(d, trans H, 1 H). HRMS (ESI) calcd for [C8H13NO3+Na] + 194.0895, found 194.1026 (M+23), 















RA-1-35 ((E)-4-(dibenzylamino)-4-oxobut-2-enoic acid). Refer to hydrolysis of monoethyl 
fumarate amides procedure for method and work up. Product produced as a yellow solid. (1.70 g, 
5.77 mmols, 95% yield).1H NMR (DMSO-d6, 400MHz) d: 4.5557 – 4.5874 (d, 2 CH2, 4 H), 
6.6870 (d, trans H, 1 H), 6.7900 (d, trans H, 1 H), 7.2496- 7.3605 (m, phenyl, 10 H). HRMS 
(ESI) calcd for [C18H17NO3+Na] + 318.1208, found 318.1484 (M+23), and 613.3032 (2M+23). 
 
XXVI 
RA-1-36 ((E)-4-(hexylamino)-4-oxobut-2-enoic acid). Refer to hydrolysis of monoethyl 
fumarate amides procedure for method and work up. Product produced as a yellow solid. (2.75 g, 
13.85 mmols, 95% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.8654 (m, CH3, 3 H), 1.2539 (m, 3 
CH2, 6 H), 1.4011 (m, CH2, 2 H), 3.0848- 3.1672 (q, CH2, 2 H), 6.3639 (d, trans H, 1 H), 6.4640 
(d, trans H, 1 H), 8.0182 (t, NH, 1 H). HRMS (ESI) calcd for [C8H13NO3+Na] +  222.1208, found 
222.1386 (M+23), and 421.2811 (2M+23). 
 
XXVII 
RA-1-38 (ethyl (E)-4-(cyclopropylamino)-4-oxobut-2-enoate). Refer to general NMM and 
iBCF Coupling procedure for method and work up. Product produced as a white solid. (0.8422 g, 
4.6 mmols, 23% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.4570 (m, CH2, 2 H), 0.6944 (m, 









trans H, 1 H), 6.9024 (d, trans H, 1 H), 8.5642 (s, NH, 1 H). HRMS (ESI) calcd for 
[C9H13NO3+Na] + 206.0895, found 206.1054 (M+23), and 389.2139 (2M+23). 
 
XXVIII 
RA-1-39 ((E)-4-(butylamino)-4-oxobut-2-enoic acid). Refer to hydrolysis of monoethyl 
fumarate amides procedure for method and work up. Product produced as a yellow solid. (2.096 
g, 12.26 mmols, quantitative yield). 1H NMR (MeOD-d4, 400MHz) d: 0.9460 (m, CH3, 3 H), 
1.3786 (m, CH2, 2 H), 1.5307 (m, CH2, 2 H), 3.2564 (m, CH2, 2 H), 6.6125 (d, trans H, 1 H), 
6.7789 (d, trans H, 1 H). HRMS (ESI) calcd for [C8H13NO3+Na] + 194.0895, found 194.1050 
(M+23), and 365.2120 (2M+23). 
 
XXIX 
RA-1-40 ((E)-4-(ethylamino)-4-oxobut-2-enoic acid). Refer to hydrolysis of monoethyl 
fumarate amides procedure for method and work up. Product produced as a yellow solid. (1.1819 
g, 7.36 mmols, quantitative yield). 1H NMR (MeOD-d4, 400MHz) d: 1.1789 (m, CH3, 3 H), 
3.2896- 3.3324 (m, CH2, 2 H), 6.6316 (d, trans H, 1 H), 6.8027 (d, trans H, 1 H). HRMS (ESI) 














RA-1-41 (ethyl (E)-4-(cyclopropylamino)-4-oxobut-2-enoate). Refer to general NMM and 
iBCF Coupling procedure for method and work up. Product produced as a white solid. (4.83 g, 
26.4 mmols, 66% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.4597 (m, CH2, 2 H) , 0.5542- 
0.6896 (m, CH2, 2 H), 1.2378 (m, CH3, 3 H), 2.7585 (q, alpha C, 1 H), 4.1731 (q, CH2, 2 H), 
6.5484 (d, trans H, 1 H), 6.8962 (d, trans H, 1 H), 8.5643 (s, NH, 1 H). HRMS (ESI) calcd for 
[C9H13NO3+Na] +  206.0895, found 206.0921 (M+23), and 389.1934 (2M+23). 
 
XXXI 
RA-1-44 (ethyl (E)-4-(cyclopropylamino)-4-oxobut-2-enoate). Refer to general NMM and 
iBCF Coupling procedure for method and work up. Product produced as a white solid. (0.183 g, 
13.6 mmols, 34% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.4574 (m, CH2, 2 H) , 0.6879 (m, 
CH2, 2 H), 1.2336 (m, CH3, 3 H), 2.7588 (q, alpha C, 1 H), 4.1748 (q, CH2, 2 H), 6.5678 (d, 
trans H, 1 H), 6.9227 (d, trans H, 1 H), 8.5656 (s, NH, 1 H). HRMS (ESI) calcd for 
[C9H13NO3+Na]+ 206.0895, found 206.1022 (M+23), and 389.2091 (2M+23). 
 
XXXII 
RA-1-45 (ethyl (E)-4-(isopropylamino)-4-oxobut-2-enoate). Refer to general NMM and iBCF 
Coupling procedure for method and work up. Product produced as a yellow solid. (2.14 g, 11.6 
mmols, 58% yield).  1H NMR (DMSO-d6, 400MHz) d: d6.1.0862 (m, 2 CH3, 6 H), 1.2310 (m, 









1 H), 8.4005 (s, NH, 1 H). HRMS (ESI) calcd for [C9H15NO3+Na]+ 208.0895, found 208.1362 
(M+23), and 393.2761 (2M+23). 
 
XXXIII 
RA-1-47. Methyl ((benzyloxy)carbonyl)- L-leucyl-L-leucinate. (20 mmols). Product produced 
as a white solid. (6.60 g, 16.8mmols, 84 % yield). 1H NMR (DMSO-d6, 400MHz) d: 0.88 (m, 4-
Leu’s CH3, 12H), 1.42-1.64 (m, CH2+CH+CH),3.61 (s, CH3, 3H), 4.08 (q, CH, 1H), 4.26 (q, CH, 
1H), 5.01 (s, CH2,2H), 7.35 (m, phenyl+ NH, 6H), 8.21 (d, NH, 1H). HRMS (ESI) calcd for 
[C21H32N2O5+Na] + 415.2311, found 415.2660 (M+23) and 807.5390 (2M+23). 
  
XXXIV 
RA-1-48. Methyl (tert-butoxycarbonyl)-L-leucyl-L-phenylalaninate. Refer to general NMM 
and iBCF Coupling procedure for method and work up. Product produced as white solid. (14.10 
g, 35.92 mmols, 89% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.82-0.87 (m, Leu CH3, 6H), 
1.28-1.37 (m, Leu CH2+ boc, 11H), 1.52 (m, Leu CH, 1H), 2.97-3.01 (m, phe CH2, m), 3.57(s, 
CH3, 3H), 3.96 (q, CH, 1H), 4.49 (q, CH, 1H), 6.80 (d, NH, 1H), 7.21-7.25 (m, phenyl, 5H), 8.21 























oxopentan-2-yl)carbamate. Refer to formation of hydrazide procedure for method and work up. 
Product produced as a white solid. (6.92 g, 16.83 mmols, quantitative yield). 1H NMR (DMSO-
d6, 400MHz) d: 0.86 (m, Leus CH3, 12H), 1.47-1.59 (m, Leus CH2 +CH, 6H), 4.05 (q, CH, 1H), 
4.20 (s, NH, 2H), 4.28 (q, CH, 1H), 5.03 (s, CH2, 2H), 7.35-7.41 (m, Phenyl+NH, 6H), 7.80 (d, 
NH, 1H), 9.13 (s, NH, 1H). HRMS (ESI) calcd for [C20H32N4O4+Na] + 415.2424, found 





Refer to Reductive Amination Procedure – Step 1 for method and work up. Product produced as 
a white solid. (7.90 g, 17.65 mmols, quantitative yield). 1H NMR (DMSO-d6, 400MHz) d: 
0.8818 (m, 4CH3, 12H), 1.0419 (m, 2CH2, 6H), 1.4329-1.6411 (m, 2CH+ 2CH2, 6H), 2.4616 (m, 


















NH, 6H), 7.7889- 7.9481 (d, NH, 1H), 10.8506-11.0220 (s, NH, 1H). HRMS (ESI) calcd for 
[C24H82N4O4+Na] + 446.2893, found 469.3366 (M+23) and 915.6783 (2M+23). 
 
XXXVII 
RA-1-51. Methyl L-leucyl-L-phenylalaninate. Refer to TFA/DCM deprotection of Boc 
protecting group procedure for method and work up. Product produced as a clear oil. (20.95 g, 
35.92 mmols, quantitative yield). 1H NMR (DMSO-d6, 400MHz) d: 0.9036 (t, 2CH3, 6H), 
1.5323-1.6632 (m, CH+CH2, 3H), 2.9990-3.0645 (m, CH2, 2H), 3.6015 (s, CH3, 3H), 3.7979 (m, 
CH, 1H), 4.5575 (m, CH, 1H), 7.2553 (m, phenyl, 5H), 8.1721 (s, 3NH, 3H), 8.9840 (d, NH, 





4-methyl-1-oxopentan-2-yl)carbamate. Refer to reductive Amination Procedure – Step 2 
(NaCNBH3 Reduction) for method and work up. Residue was then recrystallized using 1:1 
hexanes and ethyl acetate. Product produced as a white solid. (1.6732 g, 17.60 mmols, 22% 

















7H), 2.4442 (t, CH2, 2H), 4.0431 (q, CH, 1H), 4.2570 (q, CH, 1H), 4.8171 (t, CH, 1H), 5.0309 
(s, CH2, 2H), 7.3733 (m, phenyl+ NH, 6H), 7.8316 (d, NH, 1H), 9.3592 (d, NH, 1H).  HRMS 




phenylalaninate. Refer to general NMM and iBCF Coupling procedure for method and work 
up. Product produced as a White solid. (6.66 g, 17.30 mmols, 71% yield). 1H NMR (DMSO-d6, 
400MHz) d: 0.8513-0.9036 (m, 2CH3, 6H), 1.4013-1.5585 (m, boc+ CH+ CH2, 11H), 1.8597 (m, 
Hphe CH2, 2H), 2.6323 (m, Hphe CH2, 2H), 2.9990 (m, phe CH2, 2H), 3.5884 (s, CH3, 3H), 
3.9420 (m, CH, 1H), 4.4134-4.4920 (m, CH, 1H), 7.2029- 7.2553 (m, phenyl +NH, 11H), 8.6042 
(d, NH, 1H), 95079 (d, NH, 1H). HRMS (ESI) calcd for [C31H43N3O6+Na] + 576.3152, found 



























phenylalaninate. Refer to general NMM and iBCF Coupling procedure for method and work 
up. Crude was also titrated with hexanes. Product produced as a white solid. (1.53 g, 6.50 
mmols, 42% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.8685 (m, 2CH3, 6H), 1.3998 (m, Boc+ 
CH2, 11H), 1.6041 (m, Hphe CH2, 2H), 2.5952 (m, Hphe CH2, 2H), 2.9426-3.0141 (m, phe CH2, 
2H), 3.5249 (s, CH3, 3H), 3.9132 (m, CH, 1H), 4.3627-4.4343 (m, 2CH, 2H), 7.1725- 7.2849 (m, 
Phenyl +NH, 11H), 7.7344 (d, NH, 1H), 8.3679 (d, NH, 1H). HRMS (ESI) calcd for 
[C31H43N3O6+Na] + 553.3152, found 576.3594 (M+23). 
 
XLI 
RA-1-57. Methyl ((S)-2-amino-4-phenylbutanoyl)-L-leucyl-L-phenylalaninate. Refer to 
TFA/DCM deprotection of Boc protecting group procedure for method and work up. Product 
produced as a white solid. (1.72 g, 2.00 mmols, quantitative yield). 1H NMR (DMSO-d6, 
400MHz) d:  0.90 (m, Leu CH3, 6H), 1.44 (t, Leu CH2, 2H), 1.63 (q, CH, 1H), 1.92 (m, Hphe 
CH2, 2H), 2.55 (m, Hphe CH2, 2H), 2.95-3.03 (m, Phe CH2, 2H), 3.55 (s, CH3, 3H), 3.87 (m, 
CH, 1H), 4.44-4.49 (m, CH, 2H), 7.18 (m, phenyl, 10H), 8.18 (s, NH, 3H), 8.57 (m, NH, 2H). 












phenylalaninate. Refer to Morpholine coupling procedure for method and work up. 
 Product produced as a white solid. (0.3333 g, 1.240 mmols, 42% yield). 1H NMR (DMSO-d6, 
400MHz) d: 0.83-0.89 (dd, Leu CH3, 6H), 1.41 (t, CH2, 2H), 1.56 (q, CH, 1H), 1.73-1.84 (m, 
Hphe+ CH2, 4H), 2.45 (s, CH2+ Hphe CH2, 4H), 2.97-3.01 (m, N-CH2, 4H), 3.53-3.51 (s+t, O-
CH2+ CH3, 7H), 4.37-4.45 (m, 3CH, 3H), 7.18-7.28 (m, phenyl, 2H), 7.89 (d, NH, 1H), 8.04 (d, 




RA-1-59. Methyl ((S)-2-amino-4-phenylbutanoyl)-L-leucyl-L-phenylalaninate. Refer to 
TFA/DCM deprotection of Boc protecting group procedure for method and work up. Product 
produced as a white solid. (0.5074 g,0.77 mmols, quantitative yield). 1H NMR (DMSO-d6, 



















CH2, 2H), 2.95-3.03 (m, Phe CH2, 2H), 3.54 (s, CH3, 3H), 3.88 (q, CH, 1H), 4.44-4.50 (m, 2CH, 
2H), 7.07-7.31 (m, Phenyl, 10H), 0.82 (s, NH2, 2H), 8.57 (m, NH, 2H). HRMS (ESI) calcd for 




morpholinoacetamido)-4-phenylbutanamido)pentanamide. Refer to formation of hydrazide 
procedure for method and work up. (0.0806 g, 0.178 mmols, 78% yield). 1H NMR (DMSO-d6, 
400MHz) d: 0.8285-0.8718 (dd, leu-CH3, 6H), 1.3905 (m, Leu CH2, 2H), 1.5346 (q, Leu CH, 
1H), 1.7436 (q, Hphe CH2,2H), 1.8660 (m, CH2, 2H), 2.4424 (s, CH2+ Hphe CH2, 4H), 2.8243-
3.0260 (m, N-CH2+ phe CH2, 6H), 3.6168 (t, O-CH2, 4H), 4.2004 (s, NH2, 2H), 4.3517-4.4381 
(m, 3CH, 3H), 7.0967- 7.2840 (m, phenyl +NH,  11H), 7.8892 (d, NH, 1H), 8.0261 (d, NH, 1H), 

























phenylalaninate. Refer to Morpholine coupling procedure for method and work up. (0.264 g, 
3.370 mmols, 14% yield). Product produced as a white solid. 1H NMR (DMSO-d6, 400MHz) d: 
0.85-0.89 (dd, Leu CH3, 6H), 1.24 (q, Leu CH2, 2H), 1.57 (m, CH, 1H), 1.84 (q, Hphe CH2, 2H), 
2.88 (m, CH2, 2H), 2.46 (s, CH2+ Hphe CH2, 4H), 2.96-3.03 (m, N-CH2+phe CH2, 6H), 3.55 (s, 
CH3, 3H), 3.62 (t, O-CH2, 4H), 4.38 (m, CH, 1H), 4.47 (q, CH, 1H), 7.19-7.28 (m, phenyl, 10H), 
7.89 (s, NH, 1H), 8.07 (d, NH, 1H), 8.37 (d, NH, 1H). HRMS (ESI) calcd for [C33H46N4O6+H]+ 




morpholinoacetamido)-4-phenylbutanamido)pentanamide. Refer to Reductive Amination 
Procedure – Step 1 for method and work up. (0.0626 g, 0.138 mmols, 72% yield). Product 
produced as a white solid. 1H NMR (DMSO-d6, 400MHz) d: 0.8111-0.8608 (dd, Leu CH3, 6H), 
1.0200 (m, CH3, 6H), 1.3887 (m, Leu CH2, 2H), 1.5362 (q, leu CH, 1H), 1.8086-1.9172 (m, CH2, 
2H), 2.4456 (s+m, CH2+ homophe CH2, 4H), 2.8635-2.9618 (m, N-CH2, 4H), 3.6009 (t, O-CH2, 
4H), 4.3628-4.4489 (m, 2CH, 2H), 5.4354 (q, CH, 1H), 7.1895- 7.3492 (m, Phenyl, 10H), 7.8777 
(d, NH, 1H), 8.0129 (m, NH, 1H), 11.0000 (d, NH, 1H). HRMS (ESI) calcd for [C35H50N6O5+H] 

















morpholinoacetamido)-4-phenylbutanamido)pentanamide. Refer to formation of hydrazide 
procedure for method and work up. (0.2027 g, 0.3485 mmols, 96% yield). Product produced as a 
white solid. 1H NMR (DMSO-d6, 400MHz) d: 0.8108-0.8578 (dd, 2CH3, 6H), 1.3984-1.5278 (m, 
CH+CH2, 3H), 1.7391- 1.8567 (m, Hphe CH2+ CH2, 4H), 2.4442 (s, CH2+ Hphe CH2, 4H), 
2.8202- 2.9730 (m, phe CH2 + N-CH2, 6H), 3.6193 (t, O-CH3, 4H), 4.1833 (s, NH2, 2H), 4.3479- 
4.4301 (m, 3CH, 3H), 7.1661-7.2621 (m, phenyl, 10H), 7.8849- 8.0377 (d, 3NH, 3H), 9.0952 (s, 




morpholinoacetamido)-4-phenylbutanamido)pentanamide. Refer to formation of hydrazide 
procedure for method and work up. Product produced as a white solid. (0.2528 g, 0.4368 mmols, 






















CH2, 2H), 1.5308 (q, CH, 1H), 1.8678 (m, CH2, 2H), 2.4391 (s+m, CH2 +phe CH2, 4H), 2.8065-
2.9698 (m, N-CH2, 4H), 3.6026 (t, O-CH2, 4H), 4.1537 (s, NH2, 2H), 4.3272 (m, CH, 1H), 
4.4496 (q, CH, 1H), 7.1643-7.2766 (m, phenyl, 10H), 7.8889 (d, NH, 1H), 8.0318 (d, NH, 1H), 





Refer to Reductive Amination Procedure – Step 1 for method and work up. Product produced as 
a white solid. (0.49 g, 0.784 mmols, 99% yield). 1H NMR (DMSO-d6, 400MHz) d:  0.8657 (dd, 
6H, Leus CH3), 1.0312 (m, 6H, 2Methyl), 1.3877 (m, 2H, Leu CH2), 1.5405 (m, 1H, leu, CH), 
1.8206-1.8842 (m, CH+ Hphe CH2), 2.4444 (s+t, CH2 + Hphe CH2), 2.9262-3.0046 (m, Phe CH2 
+ N-CH2, 4H), 3.6157 (t, O-CH2, 4H), 4.3414-4.4178 (m, 2CH, 2H), 5.2199 (q, CH, 1H), 7.1932-
7.2569 (M, Phenyls, 10H), 7.3715 (d, NH, 1H), 7.8807 (s, N=CH, 1H), 8.0208 (m, NH, 1H), 


















phenylalaninate (2). Refer to general NMM and iBCF Coupling procedure for method and work 
up. Product produced as a white solid. (8.47 g, 15.24 mmols, 81% yield). 1H NMR (DMSO-d6, 
400MHz) d: .8655 (dd, Leu CH3, 6H), 1.4014 (s+q, Leu CH2+ Boc, 11H), 1.5868 (m, Leu CH, 
1H), 1.7929 (m, Hphe CH2, 2H), 2.5760 (t, HPhe CH2, 2H), 2.9470-2.9985 (m, Phe CH2, 2H), 
3.6343 (s, OMe, 3H), 3.9053 (m, CH, 1H), 4.3895-4.4617 (m, 2CH, 2H), 7.0377 (d, NH, 1H), 
7.1820-7.2747 (m, phenyl, 10H), 7.7384 (d, NH, 1H), 8.3566 (d, NH, 1H). HRMS (ESI) calcd 





2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide. Refer to reductive 
Amination Procedure – Step 2 (NaCNBH3 Reduction) for method and work up. Product 
produced as a white solid. (0.42 g, 0.662 mmols, 76% yield).  1H NMR (DMSO-d6, 400MHz) d: 






















2H), 2.3310-2.4537 (t +s, Hphe CH2+ CH2+ N-CH2, 8H), 2.8933-2.9751 (m+d, Phe CH2+ CH2, 
4H), 3.3227 (t, O-CH2, 4H), 4.3552 (m, 2CH+NH, 3H), 4.7540 (m, CH, 1H), 7.1769- 7.2689 (m, 
Phenyls, 10H), 78824 (d, NH, 1H), 8.0868 (d, NH, 1H), 9.2932 (s, NH, 1H). HRMS (ESI) calcd 
for [C35H52N6O5+H] +  637.3999, found: 637.4570 (M+1). 
 
LII 
RA-1-68. Methyl ((S)-2-amino-4-phenylbutanoyl)-L-leucyl-L-phenylalaninate. Refer to 
TFA/DCM deprotection of Boc protecting group procedure for method and work up. Product 
produced as a white solid. (9.34 g, 15.31 mmols, quantitative yield). 1H NMR (DMSO-d6, 
400MHz) d: .0.8077.0.9168 (m, Leu CH3, 6H), 1.4476 (t, Leu CH2, 2H), 1.6286 (m, Leu CH, 
1H), 1.9181 (t, Phe CH2, 2H), 2.5695 (t, CH2, 2H), 2.9797-3.0400 (m, CH2, 2H), 3.5467 (s, 
OMe, 3H), 3.8845 (s, CH, 1H), 4.4273-4.4877 (m, 2CH, 2H), 7.0813-7.3105 (m, phenyls, 10H), 
8.2153 (s, 2NH, 2H), 8.5772 (t, 2NH, 2H). HRMS (ESI) calcd for [C31H43N3O6+H] + 454.2628, 
found 454.3072 (M+1). 
 
LIII 
RA-1-69. Methyl (tert-butoxycarbonyl)-L-leucyl-L-phenylalaninate (5). Refer to general 


















solid. (14.87 g, 38 mmols, 95% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.8619 (m, Leu CH3, 
6H), 1.3133-1.5390 (m, Leu CH+CH3+ Boc, 12 H), 2.9549-3.0165 (m, Phe CH2, 2H), 3.5808 (s, 
OMe, 3H), 3.9707 (q, CH, 1H), 4.4940 (m, CH, 1H), 6.8025 (d, NH, 1H), 7.2232- 7.2642 (m, 





phenylalaninate. Refer to Morpholine coupling procedure for method and work up. Some 
fractions were not able to purify completely and were taken to the next step to purify. Product 
produced as a yellow solid. (3.59 g, 6.08 mmols, 37% yield). 1H NMR (DMSO-d6, 400MHz) d: 
0.8386-0.8795 (dd, Leu CH3, 6H), 1.4113 (q, Leu CH2, 2H), 1.5750 (m, Leu CH, 1H), 1.8102-
21.9022 (m, CH2, 2H), 2.4545 (t, H2C-N-CH2, 4H), 2.62 (t, CH2, 2H), 2. (s, CH2, 2H), 2.9863-
3.1499 (m, CH2, 2H), 3.2041 (s, OMe, 3H), 3.5386 (t, H2C-O-CH2, 4H), 4.3772-4.4692 (m, 
Alpha-C’s, 3H), 7.1896-7.2919 (m, Phenyl, 10H), 7.9951 (d, NH, 1H), 8.0589 (d, NH, 1H), 





















RA-1-71. Methyl L-leucyl-L-phenylalaninate. Refer to TFA/DCM deprotection of Boc 
protecting group procedure for method and work up. Product produced as a white solid. (20.51 g, 
38 mmols, quantitative yield). 1H NMR (DMSO-d6, 400MHz) d: 0.91 (m, Leu CH3, 6H), 1.54-
1.67 (m, Leu CH+CH2, 3H), 3.07 (m, Phe CH2, 2H), 3.61 (s, OMe, 3H), 3.80 (q, CH, 1H), 4.57 
(q, CH, 1H), 7.30 (m, Phenyl, 5H), 8.16 (s, NH, 3H), 8.98 (d, NH, 1H). HRMS (ESI) calcd for 




phenylalaninate. Refer to general NMM and iBCF Coupling procedure for method and work 
up. Product produced as a white solid. (19.51 g, 33.10 mmols, 84% yield). 1H NMR (DMSO-d6, 
400MHz) d: 0.8369- 0.8879 (dd, Leu CH3, 6H), 1.4186 (q, Leu CH2, 2H), 1.5819 (m, Leu CH, 
1H), 1.7758-1.8370 (m, Hphe CH2, 2H), 2.6228 (t, HPhe CH2, 2H), 2.9392 (m, Phe CH2, 2H), 
3.5311 (s, OMe, 3H), 4.0210 (m, CH, 1H), 4.3680-4.7400 (m, 2CH, 2H), 5.0416 (s, CH2, 2H), 
7.1847-7.5317 (m, phenyl, 10H), 7.5317 (d, NH, 1H), 7.8787 (d, NH, 1H), 8.3482 (d, NH, 1H). 















morpholinoacetamido)-4-phenylbutanamido)pentanamide. Refer to formation of hydrazide 
procedure for method and work up. Product produced as a white solid.  (1.39 g, 2.31 mmols, 
96% yield) with 96% yield. 1H NMR (DMSO-d6, 400MHz) d: 0.8227-0.8747 (dd, Leu CH3, 6H), 
1.3350-1.5204 (m, Leu CH2+CH, 3H), 1.8432-1.8953 (m, Hph CH2, 2H), 2.4368 (t, H2C-N-CH2, 
4H), 2.4992 (t, Hph CH2, 2H), 2.8221-2.9783 (s+m, CH2+ Phe CH2, 4H), 3.6135 (t, H2C-O-CH2, 
4H), 4.1862 (s, NH2, 2H), 4.3528-4.4361 (m, 3CH, 3H), 7.0918-7.2790 (m, Phenyls, 10H), 
7.8830 (d, NH, 1H), 8.0392 (d, NH, 1H), 9.1014 (s, NH, 1H). HRMS (ESI) calcd for 




methyl-1-oxopentan-2-yl)amino)-1-oxo-4-phenylbutan-2-yl)carbamate. Refer to formation of 

























mmols, quantitative yield). 1H NMR (DMSO-d6, 400MHz) d: 0.8182-0.8591 (dd, Leu CH3, 6H), 
1.3909 (q, Leu CH2, 2H), 1.5443 (m, Leu CH, 1H), 1.7488-1.8306 (m, Hph CH2, 2H), 2.5977 
(m, Hphe CH2, 2H), 2.8124-2.8943 (m, Phe CH2, 2H), 4.0295 (q, CH, 1H), 4.1624 (s, NH2, 2H), 
4.3056 (q, CH, 1H), 4.4283 (q, CH, 1H), 5.0624 (s, CH2, 2H), 7.1692-7.3737 (m, Phenyls, 15H), 
7.5578 (d, NH, 1H), 7,8851 (d, NH, 1H), 7.9669 (d, NH, 1H), 9.0816 (s, NH, 1H). HRMS (ESI) 




morpholinoacetamido)-4-phenylbutanamido)pentanamide. Refer to Reductive Amination 
Procedure – Step 1 for method and work up. Product produced as a white solid. (3.6985 g, 5.80 
mmols, 98% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.82-0.89 (m, 6 H, (CH3)2CH)), 1.04 (m, 6 
H, (CH3)2CH)), 1.41 (m, 2 H, CH2CH(CH3)2 ), 1.55 (m, 1 H, CH(CH3)2), 1.82-1.91 (m, 2 H, 
CH2CH2CCH), 2.46 (m, 2 H, CH2CCH), 2.46 (t ,4 H, CH2NCH2), 2.82-3.01 (m, 2 H, CH2CCH), 
2.82-3.01 (s, 2 H, CH2CNH), 3.63 (t, 4H, O-CH2), 4.38-4.47 (m, 3 H, CHCONH), 7.21-7.25 (m, 
10 H, CHCH), 7.38 (d, 1 H, NH), 7.94 (s, 1 H, CHNNH), 8.05 (m, 1 H, NH), 8.21 (d, 1 H, NH), 


















2-(2morpholinoacetamido)-4-phenylbutanamido)pentanamide. Refer to reductive Amination 
Procedure – Step 2 (NaCNBH3 Reduction) for method and work up. Product produced as a white 
solid. (3.53 g, 5.547 mmols, 95% yield). Desired product 2 was obtained as a white solid with 
95% yield.  1H NMR (DMSO-d6, 400MHz) d: 0.82-0.89 (m, 12 H, (CH3)2CH)), 1.40 (m, 2 H, 
CH2CH(CH3)2 ), 1.54 (m, 1 H, CH(CH3)2), 1.83 (m, 2 H, CH2CHCH), 2.34 (m, 2 H, 
CH2NHNH), 2.39 (t,4 H, CH2N), 2.85-2.98 (m, 2 H, CH2CCH), 2.85-2.98 (s, 2 H, CH2CNH), 
3.61 (t, 4H, O-CH2), 4.32-4.43 (m, 3 H, CHCONH), 4.76 (m, 1 H, NHNH), 7.12 (m, 1 H, NH), 
7.18-7.28 (m, 10 H, CHCH), 7.89 (d, 1 H, NH), 8.05 (d, 1 H, NH), 9.30 (d, 1 H, NH). HRMS 





























reductive Amination Procedure – Step 2 (NaCNBH3 Reduction) for method and work up. 
Product produced as a white solid. (9.50 g, 14.58 mmols, 90% yield). 1H NMR (DMSO-d6, 
400MHz) d: 0.79-0.87 (m, 12 H, (CH3)CH), 1.40-1.57 (m. 2 H, CH(CH3)) 1.40-1.57 (m, 2 H, 
CHCH2),1.80-1.88 (m, 2 H, CH2CH), 2.33 (quin, 2 H, CH2NH), 2.63 (m, 2 H, CH2CCH), 2.83-
2.90 (m, 2 H, CH2CCH), 4.03 (q, 1 H, CHCO), 4.33 (q, 1 H, CHCO), 4.43 (q, 1 H, CHCO), 4.76 
(s, 1 H, NHNH), 5.05 (s, 2 H, O-CH2), 7.12-7.37 (m, 15 H, CHCH), 7.76 (d, 1 H, NH), 7.91 (d, 1 
H, NH), 8.04 (d, 1 H, NH), 9.31 (d, 1 H, NH). HRMS (ESI) calcd for [C37H49N5O5+Na] + 




yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxo-4-phenylbutan-2-yl)carbamate.  Refer 
to reductive Amination Procedure – Step 2 (NaCNBH3 Reduction) for method and work up. 
Product produced as a white solid. (8.74 g, 13.61 mmols, 93% yield). 1H NMR (DMSO-d6, 
400MHz) d: 0.80-0.87 (m, 12 H, (CH3)CH), 1.40-1.57 (m. 2 H, CH(CH3)) 1.40-1.57 (m, 2 H, 
CHCH2),1.81-1.88 (m, 2 H, CH2CH), 2.33 (quin, 2 H, CH2NH), 2.64 (m, 2 H, CH2CCH), 2.83-
2.92 (m, 2 H, CH2CCH), 4.02 (q, 1 H, CHCO), 4.34 (q, 1 H, CHCO), 4.44 (q, 1 H, CHCO), 4.76 
(m, 1 H, NHNH), 5.06 (s, 2 H, O-CH2), 7.11-7.38 (m, 15 H, CHCH), 7.56 (d, 1 H, NH), 7.92 (d, 
1 H, NH), 8.06 (d, 1 H, NH), 9.32 (d, 1 H, NH). HRMS (ESI) calcd for [C37H49N5O5+Na]+ 
















leucyl-L-phenylalanyl)hydrazineyl)-4-oxobut-2-enoate. Refer to Aza-peptide Michael 
acceptor inhibitor synthesis coupling procedure for method and work up. Product produced as a 
yellow solid. (142.3 mg, 0.186 mmols, 59% yield). 1H NMR (DMSO-d6, 400MHz) d: 0.6671-
0.8438 (m, 12 H, (CH3)2CH), 1.1902 (m, 3 H, O-CH3), 1.4085-1.5552 (m, 4 H, CH2CH), 1.8216 
(m, 2 H, CH2CCH), 2.4385 (t, 4 H, CH2NCH2), 2.4985 (m, 2 H, CH2CH2C), 2.9511 (m, 2 H, 
CH2CCH), 2.9731 (s, 2 H, CH2), 3.6013 (t, 4 H, O-CH2), 4.1418 (m, 2 H, CHCO), 4.3651 (s, 2 
H, O-CH2), 4.5574 (q, 1 H, CHCO), 6.5400-6.5786 (d, 1 H, CHCH), 7.1581 (m, 1 H, CHCH), 
7.1581-7.2452 (m, 10H, CHCHCH), 7.8933 (d, 1 H, NH), 7.9986 (s, 1 H, NH), 8.4256 (d, 1 H, 





































L-phenylalanyl)-1-isobutylhydrazineyl)-4-oxobut-2-enoate. Refer to Aza-peptide Michael 
acceptor inhibitor synthesis coupling procedurefor method and work up. Product produced as a 
white solid. (80 mg, 0.104 mmols, 16% yield).Yield: 16%. 1H NMR (DMSO-d6, 400MHz) d: 
0.8077. 0.68-0.86 (m, 12 H, (CH3)2CH), 1.22 (m, 3 H, CH3CH2), 1.41-1.56 (m, 4 H, 
CH2(CH3)2+CH2), 1.81 (m, 2 H, CH2CCH), 2.64 (m, 2 H, CH2CH2CCH), 2.93 (s, 2 H, CH2CH), 
4.04 (q, 1 H, CHCO), 4.16 (d, 2 H, O-CH2), 4.37 (m, 1 H, CHCO), 4.55 (q, 1 H, CHCO), 5.05 (s, 
2 H, CH2OCO), 6.60 (d, 1 H, CHCH), 7.18-7.56 (m, 16 H, CCHCH+CHCH), 7.84 (s, 1 H, NH), 
7.94 (s, 1 H, NH), 8.41 (d, 1 H, NH), 10.75 (s, 1 H, NH). HRMS (ESI) calcd for 
[C43H55N5O8+H] + 770.4051, found 770.3897 (M+1). 
 
LXV 
RA-1-83. ((Benzyloxy)carbonyl)-L-leucyl-L-leucyl-L-leucine. Refer to Solid phase peptide 
synthesis procedure for method and work up. (0.0786 g, 0.16 mmols, quantitative yield). Product 
produced as a  white solid. 1H NMR (DMSO-d6, 400MHz) d: 0.8291 (m, 6-Leu’s CH3, 18H), 
1.4216-1.6118 (m, CH2+CH+CH, 9H), 4.0357 (q, CH, 1H), 4.2088 (q, CH, 1H), 4.4387 (q, CH, 
1H), 5.0213 (s, CH2,2H), 7.33455-7.4088 (m, phenyl+ NH, 6H), 7.8849 (d, NH, 1H), 8.0015 (d, 
NH, 1H). HRMS (ESI) calcd for [C26H41N3O6+H] + 492.2995, found 492.3059 (M+1), and 
















RA-1-84. ((Benzyloxy)carbonyl)-L-leucyl-L-leucyl-L-leucine . Refer to Solid phase peptide 
synthesis procedure for method and work up. Product produced as a white solid. (0.784 g, 1.60 
mmols, quantitative yield). 1H NMR (DMSO-d6, 400MHz) d: 0.8455-0.8748 (m, 6-Leu’s CH3, 
18H), 1.4248-1.6120 (m, CH2+CH+CH, 9H), 4.0403 (q, CH, 1H), 4.2129 (q, CH, 1H), 4.3562 
(q, CH, 1H), 5.0174 (s, CH2,2H), 7.3433-7.3989 (m, phenyl+ NH, 6H), 7.8816 (d, NH, 1H), 
7.9957 (d, NH, 1H). HRMS (ESI) calcd for [C26H41N3O6+H] + 492.2995, found 492.3058 (M+1). 
  
LXVII 
RA-1-89. Diethyl 2-acetoxy-3-bromosuccinate. Refer to epoxide warhead synthesis Step 1 
(bromination) for method and work up. Product produced as a yellow oil. (4.85 mmols, yield 



























RA-1-91. Diethyl 2-bromo-3-hydroxysuccinate. Refer to epoxide warhead synthesis Step 2 
(acetoxy to hydroxy group) for method and work up. Product produced as a as a yellow oil. 
(0.4314 g, 1.60 mmols, 33% yield) 1H NMR (CDCl3, 400MHz): 1.3064 (m, 6H, CH3), 4.2884 
(m, 4H, CH2), 4.6831 (d, 1H, CH), 4.7269 (d, 1H, CH). HRMS (ESI) calcd for [C8H14BrO5+Na]+ 
290.9946, found 290.9952 (M+23). 
 
LXIX 
RA-1-92. (9H-fluoren-9-yl)methyl 2-(3-(tert-butoxy)-3-oxopropyl)hydrazine-1-carboxylate . 
Refer to aza-Gln side chain synthesis (step 1) for method and work up. Product produced as a 
white solid. (0.2038 g, 522.93 µm, 13% yield). 1H NMR (DMSO-d6, 400MHz): 1.4086 (s, 9H, 
CH3), 2.2933 (t, 2H, CH2), 2.8846 (d, 2H, CH2), 4.2294 (m, 1H, NH), 4.3084 (d, 2H, CH2), 
4.6187 (s, 1H, NH), 7.3516 (m, 2H, CH), 7.4278 (m, 2H, CH), 7.6882 (m, 2H, CH), 7.8855 (m, 




RA-1-100. Diethyl 2-acetoxy-3-bromosuccinate . Refer to epoxide warhead synthesis Step 1 
(bromination) for method and work up. Product produced as a yellow oil. (13.68 g, 43.9 mmols, 













4H, CH2), 4.7996 (d, 1H, CH), 5.6065 (d, 1H, CH). HRMS (ESI) calcd for [C10H15BrO6+H] + 
311.0052, found 311.0165 (M+1). 
 
LXXI 
RA-1-101. Tert-butyl 2-(3-(tert-butoxy)-3-oxopropyl)hydrazine-1-carboxylate. Refer to aza-
Gln side chain synthesis (step 1) for method and work up. DIPEA was added via syringe pump at 
a rate of 150 µL/hour. Product produced as a white solid. (90 mg, 0.34 mmols, 3.4% yield). 1H 
NMR (CDCl3, 400MHz): 1.3894 (m, 18H, CH3), 2.5361 (t, 2H, CH2), 3.2165 (t, 2H, CH2). 
HRMS (ESI) calcd for [C12H24N2O4+H]+ 260.1736, found 261.1804 (M+1). 
 
LXXII 
RA-1-102. Diethyl 2-bromo-3-hydroxysuccinate . Refer to epoxide warhead synthesis Step 2 
(acetoxy to hydroxy group) for method and work up. Product produced as a clear oil (7.13 g, 
26.7 mmols, 60% yield). 1H NMR (CDCl3, 400MHz): 1.3271 (m, 6H, CH3), 4.2915 (m, 4H, 
CH2), 4.6708 (d, 1H, CH), 4.7256 (d, 1H, CH). HRMS (ESI) calcd for [C8H14BrO5+H]+ 



















RA-1-105. Diethyl 2-acetoxy-3-bromosuccinate. Refer to epoxide warhead synthesis Step 1 
(bromination) for method and work up. Product produced as a yellow oil. (13.17 g, 42.3 mmols, 
87% yield). 1H NMR (CDCl3, 400MHz): 1.3285 (m, 6H, CH3), 2.2042 (s, 3H, CH3), 4.3071 (m, 
4H, CH2), 4.7300 (d, 1H, CH), 4.8611 (d, 1H, CH). HRMS (ESI) calcd for [C10H15BrO6+H] + 
[C31H43N3O6+H] + 268.9954, found 269.0004 (M+1).  
 
LXXIV 
RA-1-107. Diethyl 2-bromo-3-hydroxysuccinate. Refer to epoxide warhead synthesis Step 2 
(acetoxy to hydroxy group) for method and work up. Product produced as a yellow oil. (10.12 g, 
37.9 mmols, 88% yield). 1H NMR (CDCl3, 400MHz): 1.3390 (m, 6H, CH3), 3.4432 (d, 1H, OH), 
4.2832 (m, 4H, CH2), 4.6907 (t, 1H, CH), 4.7240 (d, 1H, CH). HRMS (ESI) calcd for 
[C31H43N3O6+H] + 268.9954, found 269.0004 (M+1). 
 
LXXV 
RA-1-113. Diethyl 2-bromo-3-hydroxysuccinate. Refer to epoxide warhead synthesis Step 2 
(acetoxy to hydroxy group) for method and work up. Product produced as a clear oil. (2.87 g, 
10.68 mmols, 55%yiled). 1H NMR (CDCl3, 400MHz): 1.3336 (m, 6H, CH3), 3.4456 (d, 1H, OH), 
4.2976 (m, 4H, CH2), 4.6957 (t, 1H, CH), 4.7223 (d, 1H, CH). HRMS (ESI) calcd for 
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Instrument micrOTOFSample Name RA-1-23
Comment
Generic Display Report





Analysis Info Acquisition Date 9/24/2018 9:15:07 AM
D:\Data\Dogan\amer\RA-1-24-3.dAnalysis Name
Method Operator amer.40Tune_Low.m
Instrument micrOTOFSample Name RA-1-24-3
Comment
Generic Display Report
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Analysis Info Acquisition Date 9/19/2018 11:41:53 AM
D:\Data\Dogan\amer\RA-1-25.dAnalysis Name
Method Operator amer.40Tune_Low.m
Instrument micrOTOFSample Name RA-1-25
Comment
Generic Display Report
printed: 1 of 1Page Bruker Daltonics DataAnalysis 3.4 9/19/2018 11:44:19 AM
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Analysis Info 10/17/2018 12:00:41 PMAcquisition Date
Analysis Name D:\Data\Dogan\amer\RA-1-32-2.d
Method amer.40Tune_Low.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.4 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4500 V50 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Waste Set Divert Valve1000 m/z
Display Report
printed: 1 of 1Page 11/15/2021 2:25:29 PMBruker Daltonics DataAnalysis 3.4
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Analysis Info 10/17/2018 12:06:33 PMAcquisition Date
Analysis Name D:\Data\Dogan\amer\RA-1-33.d
Method amer.40Tune_Low.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.4 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4500 V50 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Waste Set Divert Valve1000 m/z
Display Report
printed: 1 of 1Page 11/16/2021 12:58:18 PMBruker Daltonics DataAnalysis 3.4
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Analysis Info 11/30/2018 3:07:10 PMAcquisition Date
Analysis Name D:\Data\Hadad\Leilani\RA-1-44.d
Method lottidiaz.1Tune_Low.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.4 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4500 V50 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Waste Set Divert Valve1000 m/z
Display Report
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Analysis Info 2/2/2019 2:21:02 PMAcquisition Date
Analysis Name D:\Data\Hadad\Border\RA-I-52.d
Method border.26Tune_Wide.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.4 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4500 V50 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Source Set Divert Valve3000 m/z
Display Report
printed: 1 of 1Page 11/15/2021 2:30:06 PMBruker Daltonics DataAnalysis 3.4
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Analysis Info 3/28/2019 8:56:36 PMAcquisition Date
Analysis Name D:\Data\Dogan\amer\RA-1-58-2.d
Method amer.40Tune_Low.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.4 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4500 V50 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Waste Set Divert Valve1000 m/z
Display Report





Analysis Info 3/28/2019 8:45:46 PMAcquisition Date
Analysis Name D:\Data\Dogan\amer\RA-1-59.d
Method amer.40Tune_Low.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.4 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4500 V50 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Waste Set Divert Valve1000 m/z
Display Report




Analysis Info 4/8/2019 9:18:01 PMAcquisition Date
Analysis Name D:\Data\Dogan\amer\RA-1-60.d
Method amer.40Tune_Low.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.4 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4500 V50 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Waste Set Divert Valve1000 m/z
Display Report
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Analysis Info 8/28/2019 11:40:29 AMAcquisition Date
Analysis Name D:\Data\Dogan\amer\RA-1-76-1.d
Method amer.40Tune_Low.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.4 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4500 V50 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Waste Set Divert Valve1000 m/z
Display Report





Analysis Info 9/9/2019 12:09:34 PMAcquisition Date
Analysis Name D:\Data\Dogan\amer\RA-1-77.d
Method amer.40Pos_Tuned for Masses in Mid Hundreds to 1000.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.4 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4500 V50 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Waste Set Divert Valve2000 m/z
Display Report




Analysis Info 10/7/2019 11:08:16 AMAcquisition Date
Analysis Name D:\Data\Dogan\amer\RA-1-78-A.d
Method amer.40Pos_Tuned for Masses in Mid Hundreds to 1000.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.5 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4800 V100 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Waste Set Divert Valve1000 m/z
Display Report
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Analysis Info 10/7/2019 11:01:11 AMAcquisition Date
Analysis Name D:\Data\Dogan\amer\RA-1-78-B.d
Method amer.40Pos_Tuned for Masses in Mid Hundreds to 1000.m Operator
Sample Name micrOTOFInstrument / Ser# 194
Comment
Acquisition Parameter
Positive Ion Polarity 0.5 BarSet NebulizerESI Source Type
Set Dry Heater 180 °CFocus Not active 
4.0 l/minSet Dry Gas4800 V100 m/zScan Begin Set Capillary
-500 VSet End Plate OffsetScan End Waste Set Divert Valve1000 m/z
Display Report





Analysis Info Acquisition Date 11/16/2021 9:41:54 AM
Analysis Name X:\Ozlem Dogan Ekici\Amer.40\11.16.21\RA-1-79-F_16752.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-1-79-F Instrument impact IISample Name
Comment
Generic Display Report





Analysis Info Acquisition Date 11/16/2021 9:48:22 AM
Analysis Name X:\Ozlem Dogan Ekici\Amer.40\11.16.21\RA-1-80_16754.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-1-80 Instrument impact IISample Name
Comment
Generic Display Report




Analysis Info Acquisition Date 3/9/2021 2:34:03 PM
Analysis Name X:\Ozlem Dogan Ekici\Amer.40\2021\3.9.21\RA-1-83_9081.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-1-83 Instrument impact IISample Name
Comment
Generic Display Report
Bruker Compass DataAnalysis 5.1 printed: 1 of 1Page 11/16/2021 12:44:48 PM amer.40by:
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Analysis Info Acquisition Date 3/30/2021 1:17:00 PM
Analysis Name X:\Ozlem Dogan Ekici\Amer.40\2021\3.30.21\RA-1-89_9890.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-1-89 Instrument impact IISample Name
Comment
Generic Display Report





Analysis Info Acquisition Date 6/16/2021 3:26:01 PM
Analysis Name \\files\cbc\Research-NB\Mass Spec\Impact ESI\Ozlem Dogan Ekici\Amer.40\6.16.21\RA-1-92-2.2_12299.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-1-92-2.2 Instrument impact IISample Name
Comment
Generic Display Report





Analysis Info Acquisition Date 6/24/2021 7:36:02 PM
Analysis Name \\files\cbc\Research-NB\Mass Spec\Impact ESI\Ozlem Dogan Ekici\Amer.40\6.24.21\RA-1-100_12893.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-1-100 Instrument impact IISample Name
Comment
Generic Display Report





Analysis Info Acquisition Date 7/1/2021 2:16:50 PM
Analysis Name \\files\cbc\Research-NB\Mass Spec\Impact ESI\Ozlem Dogan Ekici\Amer.40\7.1.21\RA-1-101_13086.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-1-101 Instrument impact IISample Name
Comment
Generic Display Report






Analysis Info Acquisition Date 7/13/2021 8:52:19 AM
Analysis Name \\files\cbc\Research-NB\Mass Spec\Impact ESI\Ozlem Dogan Ekici\Amer.40\7.13.21\RA-102_13236.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-102 Instrument impact IISample Name
Comment
Generic Display Report




Analysis Info Acquisition Date 7/21/2021 2:24:34 PM
Analysis Name X:\Ozlem Dogan Ekici\Amer.40\2021\7.21.21\RA-1-105_13501.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-1-105 Instrument impact IISample Name
Comment
Generic Display Report
Bruker Compass DataAnalysis 5.1 printed: 1 of 1Page 11/15/2021 2:54:13 PM amer.40by:
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Analysis Info Acquisition Date 7/29/2021 12:05:43 PM
Analysis Name X:\Ozlem Dogan Ekici\Amer.40\2021\7.28.21\RA-1-107_13858.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-1-107 Instrument impact IISample Name
Comment
Generic Display Report




Analysis Info Acquisition Date 10/15/2021 10:57:57 AM
Analysis Name X:\Ozlem Dogan Ekici\Amer.40\10.15.21\RA-1-113_16102.d
CBC Mass Spec FacilityMethod Autosampler Tune Low.m Operator
RA-1-113 Instrument impact IISample Name
Comment
Generic Display Report
Bruker Compass DataAnalysis 5.1 printed: 1 of 1Page 10/19/2021 2:16:55 PM amer.40by:
